IP Library › Granted Patent US 9,827,294
Granted Patent B2
US 9,827,294 · App. 15/171,327 · Granted Nov 28, 2017

Treatments for migraine and related disorders

Inventors: Richard Kraig (Chicago, IL); Aya Pusic (Chicago, IL); Heidi Mitchell (Dubuque, IA); Yelena Grinberg (Riverside, CA); Marcia Kraig (Chicago, IL)
Assignee: The University of Chicago
A61K38/217A61K9/0043A61K31/00A61K38/18A61K38/2073A61K38/28A61K38/30A61K45/06A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,827,294
App. No.
15/171,327
Granted
Nov 28, 2017
Kind
B2
Abstract

Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies for migraine events and related headaches.

Claims (16)

1. A method for treating a migraine patient comprising administering to the patient an effective amount of a composition comprising IGF-1, wherein the treating excludes administering a cytokine to the patient.

2. The method of claim 1 , further comprising administering insulin.

3. The method of claim 1 , wherein the patient is suffering from a migraine headache when the composition is administered.

4. The method of claim 1 , wherein the composition is administered to the patient intranasally.

5. The method of claim 1 , wherein the composition comprises between about 0.1 ng and about 2.0 g of IGF-1.

6. The method of claim 1 , wherein the patient is administered up to about 10 ml of the composition.

7. The method of claim 1 , further comprising administering the composition to the patient up to two times a week.

8. The method of claim 1 , wherein the patient is administered the composition every 4 to 8 hours.

9. The method of claim 1 , wherein the patient is administered the composition once a day.

10. The method of claim 1 , wherein the composition is administered to the patient's brain cells.

11. The method of claim 1 , wherein the composition is administered to microglia or other brain cell types in the patient's brain.

12. The method of claim 1 , wherein the patient has experienced more than four migraines in a 4 week period.

13. The method of claim 1 , wherein the patient is also administered an analgesic or a non IGF-1 anti-migraine drug.

14. The method of claim 13 , wherein the composition includes the analgesic or additional anti-migraine drug.

15. The method of claim 4 , wherein the composition is administered to the patient with a nasal delivery device.

16. The method of claim 1 , wherein the patient is not suffering from a migraine headache when the composition is administered.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 28, 2016
From: UNIVERSITY OF CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040166/0586 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2016
From: KRAIG, RICHARD; PUSIC, AYA; MITCHELL, HEIDI; GRINBERG, YELENA; KRAIG, MARCIA
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 038783/0637 →
Continuity (3)
Continuation 14234276
Provisional Application 61510673 · Jul 22, 2011
Related Publication 20160263194A1 · Sep 15, 2016